Chief Financial and Business Officer · Cue Biopharma, Inc. (CUE)

Lucinda Warren

FY2025 is the first fiscal year CompBrief holds for Lucinda Warren as a named executive officer of Cue Biopharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$801,223

Salary $469,952Stock awards $0

4th of 5 named executive officers at Cue Biopharma by FY2025 total.

5 named officers on file for Cue Biopharma, FY2025

Lucinda Warren’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cue Biopharma’s whole pay program stands against its peers

  • Cue Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CUE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 16, 2026 (DEF 14A).

Free

Get Lucinda Warren’s full pay file as a PDF — free

More than this page: up to 10 years of Lucinda’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Lucinda Warren compensation by year

Cue Biopharma Summary Compensation Table · the one fiscal year held
In US dollars, as Cue Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$469,952
Bonus$0
Stock awards$0
Option awards$330,275
Non-equity incentive$0
Pension and deferred compensation$0
All other$996
Total$801,223

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cue Biopharma, Inc. DEF 14A filed March 16, 2026, accession 0001193125-26-108301, and prior-year filings.

How this page was built: the Cue Biopharma, Inc. filed document, accession 0001193125-26-108301. Every figure is read from that document and cited to the page and table it appears in. Filed March 16, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option175,000—$0.66
Option218,750—$0.98
Option125,000—$0.72

Per the Outstanding Equity Awards at Fiscal Year-End table in Cue Biopharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Cue Biopharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Daniel PasseriFormer Chief Executive Officer$1,426,183
Matteo LevisettiFormer Chief Medical Officer$1,219,364
Usman AzamPresident and Chief Executive Officer$1,185,639
Lucinda Warren · this pageChief Financial and Business Officer$801,223
Colin SandercockSVP, General Counsel and Secretary$599,222

The full Cue Biopharma compensation record

free company brief

This page is one person within Cue Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cue Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lucinda Warren's compensation dossier · One-time report. No refunds.